|
| Friday, June 7, 2019 |
|
|
PromarkerD features at American Diabetes Association 79th Scientific Sessions saying diabetics deserve to know their future kidney disease status |
| Proteomics International (ASX: PIQ) has been invited to feature on the American Diabetes Association (ADA) TV News Network as a key opinion leader (KOL) on diabetic kidney disease diagnostics, which includes an update on PromarkerD, during the ADA 79th Scientific Sessions conference in San Francisco, June 7-11, 2019. more info >> |
|
| Monday, June 3, 2019 |
|
|
Proteomics International and PromarkerD at BIO 2019 saying 30 million diabetics in US deserve to know their future kidney disease status |
| Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) will have a stand #2349 at the BIO International Convention (Philadelphia, June 3-6, 2019). more info >> |
|
| Monday, June 4, 2018 |
|
|
Proteomics國際與PrismHealthDx 締約在美國啟動PromarkerD糖尿病腎臟疾病預測測試 |
| 醫藥技術公司Proteomics國際（Proteomics國際實驗室有限公司；ASX: PIQ）已經與美國精密醫療和診斷服務實驗室PrismHealthDx 股份有限公司( PHDx )簽署了首個許可協議，聯手在美國啟動全球領先的PromarkerD糖尿病腎病預測測試。 more info >> |
|
|
Proteomics国际与PrismHealthDx 缔约在美国启动PromarkerD糖尿病肾脏疾病预测测试 |
| 医药技术公司Proteomics国际（Proteomics国际实验室有限公司；ASX: PIQ）已经与美国精密医疗和诊断服务实验室PrismHealthDx 股份有限公司(PHDx )签署了首个许可协议，联手在美国启动全球领先的PromarkerD糖尿病肾病预测测试。 more info >> |
|
|
Proteomics International signs with PrismHealthDx for US launch of PromarkerD predictive test for diabetic kidney disease |
| Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has signed the first licence agreement for its world-leading PromarkerD predictive test for diabetic kidney disease in the United States. more info >> |
|
| Tuesday, March 20, 2018 |
|
|
PromarkerD Diagnostic Test Leader Officially Launched |
Medical technology company Proteomics International Laboratories Ltd (Proteomics International;
ASX: PIQ) has announced the official product launch of its world leading predictive diagnostic test for diabetic kidney disease, "PromarkerD". more info >> |
|
| Monday, February 12, 2018 |
|
|
Proteomics International announces Strategic Alliance and Investment in CPR Pharma Services |
| MedTech pioneer Proteomics International (PILL; ASX: PIQ) has entered into a strategic alliance with CPR Pharma Services (CPR), targeting the high growth area of clinical trials and related research, with an offer to acquire 10% of CPR's share capital through the issue of 4 million PIQ shares. more info >> |
|
| Monday, June 12, 2017 |
|
|
Clinical Validation Results confirm PromarkerD can predict Diabetic Kidney Disease better than any Current Measure |
| Proteomics International Laboratories Ltd (ASX: PIQ) (PILL) announced today results from its validation clinical study showing that the PromarkerD blood test can predict the onset of diabetic kidney disease better than any current measure. more info >> |
|
| Tuesday, March 28, 2017 |
|
|
Frost & Sullivan independent industry report identifies PromarkerD as the world leading test for Diabetic Kidney Disease |
| Proteomics International Laboratories Ltd (PILL; ASX:PIQ) is the leader in predictive diagnostics for diabetic kidney disease, according to an independent Frost & Sullivan report released this month. more info >> |
|
| Monday, March 27, 2017 |
|
|
Frost & Sullivan independent industry report identifies PromarkerD as the world leading test for Diabetic Kidney Disease |
| Proteomics International Laboratories Ltd (PILL; ASX:PIQ) is the leader in predictive diagnostics for diabetic kidney disease, according to an independent Frost & Sullivan report released this month. more info >> |
|
|
|
|
